Those affiliated with some smaller companies have privately described the choice of Mr. O’Neill as a   scenario that could send the drug industry into chaos. The F. D. A. they say, is not perfect, but its standards provide a level playing field on which both big and small companies can compete. " We’re not selling   and Pepsi, where patients can taste the   and decide if they like it," said John M. Maraganore, the chief executive of Alnylam Pharmaceuticals, a Massachusetts biotech firm. 